Premium
Characterization of urinary CD 4 + and CD 8 + T cells in kidney transplantation patients with polyomavirus BK infection and allograft rejection
Author(s) -
Doesum W.B.,
Abdulahad W.H.,
Dijk M.C.R.F.,
Dolff S.,
Son W.J.,
Stegeman C.A.,
Sanders J.S.F.
Publication year - 2014
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12273
Subject(s) - bk virus , medicine , urinary system , transplantation , kidney , urine , kidney transplantation , chronic allograft nephropathy , nephropathy , immunology , t cell , urology , immune system , endocrinology , diabetes mellitus
Background and objectives The objective of this study was to characterize CD 4 + and CD 8 + T‐cell populations in blood and urine of renal transplant patients with BK virus ( BKV ) infection or allograft rejection. Materials and methods Percentages and absolute numbers of CD 4 + and CD 8 + effector memory T‐cell subtype (T EM ) and terminal differentiated T cells (T TD ) in renal transplant patients with BKV infection ( n = 14), with an episode of allograft rejection ( n = 9), and in uncomplicated renal transplant patients with a stable kidney function ( n = 12) were measured and compared using 4‐color fluorescence‐activated cell sorting. Results were correlated with the number of CD 4 + and CD 8 + T cells in renal biopsies. Results In patients with allograft rejection, the number of urinary CD 4 + T EM and CD 8 + T EM cells was significantly increased compared to patients with BKV infection or patients without complications. Positive correlation was found between the number of CD 4 + and CD 8 + cells in the renal biopsies and the number of CD 4 + and CD 8 + cells in urine. In patients with rejection, after 2 months of immunosuppressive therapy, a reduction in urinary CD 8 + T EM cells was found. Conclusions CD 4 + T EM and CD 8 + T EM cells in urine could be a marker to distinguish allograft rejection from BKV ‐associated nephropathy and to monitor therapy effectiveness in renal transplant patients with allograft rejection.